CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.) コンサ―ト・ファ―マシュ―ティカルズ

 CNCEのチャート


 CNCEの企業情報

symbol CNCE
会社名 Concert Pharmaceuticals Inc (コンサ―ト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コンサート・ファーマスーティカル(Concert Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は小分子医薬品の発見と開発に従事する。同社は医薬品の開発を通じて事業を行う。同社の重水素化化学物質プラットフォーム(DCEプラットフォーム)は各種治療領域にある可能性を有する。同社の製品好捕にはAVP-786、CTP-656、CTP-730、CTP-543、JZP-386等を含む。同社の製品候補であるCTP-656は、G551D突然変異を含むゲーティング変異を有する患者にある嚢胞性線維症の治療のために開発中次世代増強剤である。CTP-543はルキソリチニブを改変することでコンサートのジュウテリウム化学技術を応用することにより発見された。AVP-786はデキストロメトルファンと超低用量のキニジンの組み合わせである。CTP-730は各種炎症性疾患の治療の可能性を有するホスホジエステラーゼ4(PDE4)阻害剤である。   コンサ―ト・ファ―マシュ―ティカルズは、米国のバイオ医薬品企業。臨床段階の低分子薬の開発に従事。主要パイプライン製品候補は、多発性硬化症および脊髄損傷に関連した痙性のためのCTP-354、糖尿病性腎症のためのCTP-499、神経学的および精神障害のためのAVP-786など。   Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
本社所在地 99 Hayden Avenue Suite 500 Lexington MA 02421 USA
代表者氏名 Richard H. Aldrich リチャードH.アルドリッチ
代表者役職名 Independent Chairman of the Board Co-Founder
電話番号 +1 781-860-0045
設立年月日 38808
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 64人
url www.concertpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cnce
adr_tso
EBITDA EBITDA(百万ドル) 101.93900
終値(lastsale) 15.5
時価総額(marketcap) 362932887.5
時価総額 時価総額(百万ドル) 337.17640
売上高 売上高(百万ドル) 154.33700
企業価値(EV) 企業価値(EV)(百万ドル) 147.00540
当期純利益 当期純利益(百万ドル) 103.45900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Concert Pharmaceuticals Inc revenues increased from $35K to $10.5M. Net loss applicable to common stockholders decreased 32% to $17.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General_Admin exp decrease of 14% to $7.8M (expense) Investment Income increase from $292K to $1.3M (income).

 CNCEのテクニカル分析


 CNCEのニュース

   Enslaving stocks: Snap Inc. (NYSE:SNAP 9.48%), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE 0.12%)  2023/03/07 12:32:50 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enslaving stocks: Snap Inc. (NYSE:SNAP 9.48%), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE 0.12%) appeared first on Stocks Equity .
   Sun Pharma completes acquisition of US-based Concert Pharmaceuticals  2023/03/06 17:09:00 Business Standard
Drug major Sun Pharma on Monday said it has completed the acquisition of US-based Concert Pharmaceuticals. In January, the Mumbai-based company inked a pact to acquire Concert in a USD 576 million deal. The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing. "We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub," Sun Pharma North America CEO Abhay Gandhi said. By bringing together Concert''s talented team with Sun Pharma''s global reach and commercial capabilities, this acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patien
   Sun Pharmaceutical Completes Acquisition Of Concert Pharmaceuticals  2023/03/06 15:03:41 BQ Prime
Drug major Sun Pharma on Monday said it has completed the acquisition of U.S.-based Concert Pharmaceuticals.
   Sun Pharma Completes Acquisition of Concert Pharmaceuticals  2023/03/06 13:39:00 PR Newswire
Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma''s Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J., March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO,…
   Concert Pharmaceuticals Inc. (NASDAQ: CNCE): Aiming For A Higher Share Price  2023/03/04 13:30:00 Stocks Register
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares, rose in value on Friday, 03/03/23, with the stock price up by 0.12% to the previous day’s close as strong demand from buyers drove the stock to $8.37. Actively observing the price movement in the last trading, the stock closed the session at $8.36, falling within a range of $8.35 … Concert Pharmaceuticals Inc. (NASDAQ: CNCE): Aiming For A Higher Share Price Read More »
   Concert Pharmaceuticals: Negative Spread But Interesting CVR  2023/02/16 18:54:09 Seeking Alpha
Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. Click here for my take on CNCE stock now.
   Concert retains breakthrough status for hair loss therapy despite rival entry  2023/02/15 18:54:20 Seeking Alpha
Concert Pharmaceuticals (CNCE) announced Wednesday that the FDA allowed it to keep the Breakthrough Therapy Designation for hair loss therapy deuruxolitinib. Read the full story here.
   Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata  2023/02/15 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.
   Watch this stock’s price performance: Concert Pharmaceuticals Inc. (NASDAQ:CNCE)  2023/02/09 20:00:00 US Post News
Currently, Concert Pharmaceuticals Inc.’s (CNCE) stock is trading at $8.34, marking a fall of -0.12% from last night’s close. At this price, the stock is -1.18% below its 52-week high of $8.44 and 224.51% above its 52-week low of $2.57. Based on the past 30-day period, the stock price is -1.18% below the high and […]
   SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations  2023/02/06 21:53:00 Kwhen Finance
   Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021  2021/07/29 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on August 5, 2021 to discuss its second quarter financial results and provide a business update.
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues  2021/07/14 11:48:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) (IPOed Tuesday) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc.
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コンサ―ト・ファ―マシュ―ティカルズ CNCE Concert Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)